1735TiP NETTER-3: A phase III study of [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, grade 1 and grade 2 (Ki-67<10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden. - Singh, S.; Capdevila, J.; Halfdanarson, T.R.; Halperin, D.; Herrmann, K.; Pavel, M.E.; Xu, J.; Pathak, D.; Kunz, P.L. (Annals of Oncology, 2025)